These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 36163355)

  • 21. Type and Pattern of Alcohol Consumption is Associated With Liver Fibrosis in Patients With Non-alcoholic Fatty Liver Disease.
    Mitchell T; Jeffrey GP; de Boer B; MacQuillan G; Garas G; Ching H; Hamdorf J; Adams LA
    Am J Gastroenterol; 2018 Oct; 113(10):1484-1493. PubMed ID: 29899440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of MAFLD and NAFLD diagnostic criteria in real world.
    Lin S; Huang J; Wang M; Kumar R; Liu Y; Liu S; Wu Y; Wang X; Zhu Y
    Liver Int; 2020 Sep; 40(9):2082-2089. PubMed ID: 32478487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of metabolic dysfunction-associated fatty liver disease using FibroScan, diet, and microbiota: A large cross-sectional study.
    Tateda T; Iino C; Sasada T; Sato S; Igarashi G; Kawaguchi S; Mikami K; Endo T; Sawada K; Mikami T; Fukuda S; Nakaji S; Sakuraba H
    PLoS One; 2022; 17(11):e0277930. PubMed ID: 36417462
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic-associated fatty liver disease and the risk of cardiovascular disease.
    Zhang P; Dong X; Zhang W; Wang S; Chen C; Tang J; You Y; Hu S; Zhang S; Wang C; Wen W; Zhou M; Tan T; Qi G; Li L; Wang M
    Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102063. PubMed ID: 36494073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Moderate alcohol consumption is not associated with subclinical cardiovascular damage but with hepatic fibrosis in non-alcoholic fatty liver disease.
    Kashiwagi K; Yamaguchi A; Shiba S; Taniki N; Inoue N; Takaishi H; Iwao Y; Kanai T
    Alcohol; 2020 Dec; 89():1-7. PubMed ID: 32738385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD.
    Nguyen VH; Le MH; Cheung RC; Nguyen MH
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2172-2181.e6. PubMed ID: 34033923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis.
    Kimura T; Tanaka N; Fujimori N; Sugiura A; Yamazaki T; Joshita S; Komatsu M; Umemura T; Matsumoto A; Tanaka E
    World J Gastroenterol; 2018 Apr; 24(13):1440-1450. PubMed ID: 29632425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Do MAFLD Patients with Harmful Alcohol Consumption Have a Different Dietary Intake?
    Policarpo S; Carvalhana S; Craciun A; Crespo RR; Cortez-Pinto H
    Nutrients; 2022 Mar; 14(7):. PubMed ID: 35405948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discrepancies between Nonalcoholic and Metabolic-associated Fatty Liver Disease by Multiple Steatosis Assessment.
    Shao C; Ye J; Li X; Lin Y; Feng S; Liao B; Wang W; Gong X; Zhong B
    J Clin Transl Hepatol; 2022 Dec; 10(6):1013-1026. PubMed ID: 36381107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic dysfunction-associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality.
    van Kleef LA; de Knegt RJ; Brouwer WP
    Hepatology; 2023 Mar; 77(3):942-948. PubMed ID: 35776631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups.
    Kim H; Lee CJ; Ahn SH; Lee KS; Lee BK; Baik SJ; Kim SU; Lee JI
    Dig Dis Sci; 2022 Oct; 67(10):4919-4928. PubMed ID: 35579799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD.
    Lim GEH; Tang A; Ng CH; Chin YH; Lim WH; Tan DJH; Yong JN; Xiao J; Lee CW; Chan M; Chew NW; Xuan Tan EX; Siddiqui MS; Huang D; Noureddin M; Sanyal AJ; Muthiah MD
    Clin Gastroenterol Hepatol; 2023 Mar; 21(3):619-629.e7. PubMed ID: 34871813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Ability of Lipoprotein (a) Level to Predict Early Carotid Atherosclerosis Is Impaired in Patients With Advanced Liver Fibrosis Related to Metabolic-Associated Fatty Liver Disease.
    Wu T; Ye J; Shao C; Lin Y; Wang W; Feng S; Zhong B
    Clin Transl Gastroenterol; 2022 Jul; 13(7):e00504. PubMed ID: 35608296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic-associated fatty liver disease (MAFLD) in coeliac disease.
    Rispo A; Imperatore N; Guarino M; Tortora R; Alisi A; Cossiga V; Testa A; Ricciolino S; Fiorentino A; Morisco F
    Liver Int; 2021 Apr; 41(4):788-798. PubMed ID: 33319459
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interaction of metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease with advanced fibrosis in the death and intubation of patients hospitalized with coronavirus disease 2019.
    Vázquez-Medina MU; Cerda-Reyes E; Galeana-Pavón A; López-Luna CE; Ramírez-Portillo PM; Ibañez-Cervantes G; Torres-Vázquez J; Vargas-De-León C
    Hepatol Commun; 2022 Aug; 6(8):2000-2010. PubMed ID: 35438253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
    Yoneda M; Yamamoto T; Honda Y; Imajo K; Ogawa Y; Kessoku T; Kobayashi T; Nogami A; Higurashi T; Kato S; Hosono K; Saito S; Nakajima A
    J Gastroenterol; 2021 Nov; 56(11):1022-1032. PubMed ID: 34601620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MAFLD and NAFLD in the prediction of incident chronic kidney disease.
    Kwon SY; Park J; Park SH; Lee YB; Kim G; Hur KY; Koh J; Jee JH; Kim JH; Kang M; Jin SM
    Sci Rep; 2023 Jan; 13(1):1796. PubMed ID: 36720976
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fibrosis Burden of Missed and Added Populations According to the New Definition of Metabolic Dysfunction-Associated Fatty Liver.
    Park H; Yoon EL; Kim M; Kim JH; Cho S; Jun DW; Nah EH
    J Clin Med; 2021 Oct; 10(19):. PubMed ID: 34640643
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of moderate alcohol drinking in nonalcoholic fatty liver disease.
    Choi JH; Sohn W; Cho YK
    Clin Mol Hepatol; 2020 Oct; 26(4):662-669. PubMed ID: 32971586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of body fat accumulation on metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease in Japanese male young adults.
    Miwa T; Francisque C; Tajirika S; Hanai T; Imamura N; Adachi M; Horita R; Menezes LJ; Kawaguchi T; Shimizu M; Yamamoto M
    Hepatol Res; 2023 Aug; 53(8):691-700. PubMed ID: 37143429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.